Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (311-320 of 349) with videos related to

Pageof 35
Sort By:
Epigenetics|September 28, 2011
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman, Solange Mongoue-Tchokote, Angela Gibbs, et al.
European Urology|May 24, 2020
Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical TrialHiten D Patel, Farzana A Faisal, Bruce J Trock, et al.
The Prostate|March 26, 2008
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African AmericansJielin Sun, Lina Purcell, Zhengrong Gao, et al.
BJU International|October 16, 2016
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancerStacy Loeb, Sanghyuk S Shin, Dennis L Broyles, et al.
The Journal of Urology|January 18, 2011
Predicting 15-year prostate cancer specific mortality after radical prostatectomyScott E Eggener, Peter T Scardino, Patrick C Walsh, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosisSamir S Taneja, Elias I Hsu, Carol D Cheli, et al.
Medical Oncology (Northwood, London, England)|April 28, 2022
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancerDiane K Reyes, Bruce J Trock, Phuoc T Tran, et al.
Clinical Chemistry|October 15, 2011
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technologyDavid H Wilson, David W Hanlon, Gail K Provuncher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Association of prostate cancer risk variants with clinicopathologic characteristics of the diseaseJianfeng Xu, Sarah D Isaacs, Jielin Sun, et al.
The Journal of Urology|April 22, 2014
Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsiesAlan W Partin, Leander Van Neste, Eric A Klein, et al.
Pageof 35

Showing results (311-320 of 349) with videos related to

Sort By:
Pageof 35
Epigenetics|September 28, 2011
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman, Solange Mongoue-Tchokote, Angela Gibbs, et al.
European Urology|May 24, 2020
Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical TrialHiten D Patel, Farzana A Faisal, Bruce J Trock, et al.
The Prostate|March 26, 2008
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African AmericansJielin Sun, Lina Purcell, Zhengrong Gao, et al.
BJU International|October 16, 2016
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancerStacy Loeb, Sanghyuk S Shin, Dennis L Broyles, et al.
The Journal of Urology|January 18, 2011
Predicting 15-year prostate cancer specific mortality after radical prostatectomyScott E Eggener, Peter T Scardino, Patrick C Walsh, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosisSamir S Taneja, Elias I Hsu, Carol D Cheli, et al.
Medical Oncology (Northwood, London, England)|April 28, 2022
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancerDiane K Reyes, Bruce J Trock, Phuoc T Tran, et al.
Clinical Chemistry|October 15, 2011
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technologyDavid H Wilson, David W Hanlon, Gail K Provuncher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Association of prostate cancer risk variants with clinicopathologic characteristics of the diseaseJianfeng Xu, Sarah D Isaacs, Jielin Sun, et al.
The Journal of Urology|April 22, 2014
Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsiesAlan W Partin, Leander Van Neste, Eric A Klein, et al.
Pageof 35